PMID- 19826177
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20181201
IS  - 1899-1505 (Electronic)
IS  - 0867-5910 (Linking)
VI  - 60
IP  - 3
DP  - 2009 Sep
TI  - Helicobacter pylori infection in gastric cancerogenesis.
PG  - 3-21
AB  - Gastric cancer (GS) remains one of the most common cancers worldwide. It is 
      considered as the second most frequent cause of cancer death worldwide, although 
      much geographical variation in incidence exists. Many studies before linked 
      Helicobacter pylori (Hp) which is now considered as an important pathogen, to the 
      risk of developing noncardia GS. This overview attempts to summarize the recent 
      basic and clinical evidence on the link between H. pylori and gastric cancer, 
      after the award of the Nobel Prize for Physiology or Medicine to Drs. J.R. Warren 
      and B.J. Marshall for the first culture and isolation of Hp and the investigation 
      of their relevance to peptic ulcer disease. It become evident that Hp eradication 
      by antibiotic treatment combined with proton pump inhibitor (PPI) serves as the 
      primary chemoprevention strategy to reduce gastric cancer incidence. Moreover, 
      the eradication therapy reduces gastric cancer incidence in patients without any 
      precancerous lesions at the baseline and is most effective before the development 
      of atrophic gastritis. Due to understanding the molecular nature of GC which has 
      been nowadays under intense investigation, our review attempts to highlight 
      recent progress in the field of research on Hp-induced GS. We discuss the 
      geographical diversity in Hp infection and cancer incidence and the mechanistic 
      role of gastrin, cyclooxygenase-2 (COX-2), growth factor, nitric oxide (NO)/NO 
      synthase and E-cadherin/beta-cathenin systems, apoptosis and angiogenesis in 
      Hp-induced gastric carcinogenesis. In addition host-related genetic 
      susceptibility and the role of overexpression of a proinflammatory cytokines and 
      their polymorphism is discussed in the relation to the cascade of events such as 
      gastric atrophy, intestinal metaplasia and dysplasia that finally lead to 
      adenocarcinoma.
FAU - Konturek, P C
AU  - Konturek PC
AD  - First Department of Medicine, University Erlangen-Nuremberg, Ulmenweg 18, 91054 
      Erlangen Germany.
FAU - Konturek, S J
AU  - Konturek SJ
FAU - Brzozowski, T
AU  - Brzozowski T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - J Physiol Pharmacol
JT  - Journal of physiology and pharmacology : an official journal of the Polish 
      Physiological Society
JID - 9114501
RN  - 0 (Gastrins)
SB  - IM
MH  - Animals
MH  - Gastric Mucosa/immunology/metabolism/microbiology/pathology
MH  - Gastrins/metabolism
MH  - Helicobacter Infections/*complications/drug 
      therapy/immunology/metabolism/microbiology
MH  - Helicobacter pylori/drug effects/genetics/isolation & purification/*pathogenicity
MH  - Humans
MH  - Prevalence
MH  - Stomach Neoplasms/epidemiology/*etiology/immunology/metabolism/prevention & 
      control
MH  - Virulence
RF  - 116
EDAT- 2009/10/15 06:00
MHDA- 2010/03/31 06:00
CRDT- 2009/10/15 06:00
PHST- 2009/01/14 00:00 [received]
PHST- 2009/07/15 00:00 [accepted]
PHST- 2009/10/15 06:00 [entrez]
PHST- 2009/10/15 06:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
PST - ppublish
SO  - J Physiol Pharmacol. 2009 Sep;60(3):3-21.